Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Optimizing MM treatment through understanding resistance

Michel Delforge • 17 May 2019
COMy 2019
Multiple Myeloma

Multiple myeloma (MM) cells can become resistant to certain drugs or combinations of drugs. Michel Delforge, MD, PhD, of the University of Leuven, Leuven, Belgium, explains that understanding the mechanisms of resistance in MM will allow for the optimization of drug choice. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Michel Delforge

Cevostamab in patients with triple-class refractory MM after prior BCMA-targeted bispecific antibody 2:27
Cevostamab in patients with triple-class refractory MM after prior BCMA-targeted bispecific antibody
Michel Delforge • 6 Dec 2024
RPM for early CRS detection in patients with multiple myeloma receiving bispecific antibodies 2:37
RPM for early CRS detection in patients with multiple myeloma receiving bispecific antibodies
Michel Delforge • 6 Dec 2024
The importance of the multidisciplinary team in the successful deployment of CAR-T therapies 1:18
The importance of the multidisciplinary team in the successful deployment of CAR-T therapies
Michel Delforge • 6 Dec 2024
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3 2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals